WALDENCAST PLC (WALD)
Waldencast Announces Sale of Obagi Medical to Bridgepoint
BRISTOL MYERS SQUIBB CO (BMY)
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol-Myers Squibb Company (BMY)
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
BAUSCH + LOMB CORPORATION COMMON SHARES (BLCO)
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb - Bristol Myers Squibb AnnouncesOpdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
BRISTOL MYERS SQUIBB CO (BMY)
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
DOLLAR GENERAL CORP (DG)
Dollar General Announces “Stars, Stripes and Savings” Event with 30 Days of Deals Ahead of America’s 250th Anniversary
Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
Bristol-Myers Squibb Co. (BMYMP)
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
EASON TECHNOLOGY LTD (DXF)
Eason Technology Announces the Formation of New Subsidiary, Four Ele Industrial Intelligent Tech to Target Power Energy, Energy Networks and New Energy Storage Facilities Scenarios